- Home
- TGTX vs RLI Comparison
TGTX vs RLI Comparison
Compare TGTX & RLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- RLI
- Stock Information
- Founded
- TGTX 1993
- RLI 1965
- Country
- TGTX United States
- RLI United States
- Employees
- TGTX N/A
- RLI N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- RLI Property-Casualty Insurers
- Sector
- TGTX Health Care
- RLI Finance
- Exchange
- TGTX Nasdaq
- RLI Nasdaq
- Market Cap
- TGTX 5.1B
- RLI 6.1B
- IPO Year
- TGTX 1995
- RLI 1985
- Fundamental
- Price
- TGTX $36.73
- RLI $64.72
- Analyst Decision
- TGTX Strong Buy
- RLI Hold
- Analyst Count
- TGTX 6
- RLI 8
- Target Price
- TGTX $47.50
- RLI $75.83
- AVG Volume (30 Days)
- TGTX 1.9M
- RLI 617.4K
- Earning Date
- TGTX 11-03-2025
- RLI 10-20-2025
- Dividend Yield
- TGTX N/A
- RLI 4.09%
- EPS Growth
- TGTX N/A
- RLI N/A
- EPS
- TGTX 0.36
- RLI 3.50
- Revenue
- TGTX $454,069,000.00
- RLI $1,816,602,000.00
- Revenue This Year
- TGTX $82.22
- RLI N/A
- Revenue Next Year
- TGTX $47.76
- RLI $4.05
- P/E Ratio
- TGTX $101.18
- RLI $18.42
- Revenue Growth
- TGTX 30.96
- RLI 11.69
- 52 Week Low
- TGTX $21.16
- RLI $62.04
- 52 Week High
- TGTX $46.48
- RLI $91.15
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- RLI 43.96
- Support Level
- TGTX $34.52
- RLI $62.04
- Resistance Level
- TGTX $37.45
- RLI $65.23
- Average True Range (ATR)
- TGTX 1.10
- RLI 1.11
- MACD
- TGTX 0.59
- RLI 0.02
- Stochastic Oscillator
- TGTX 90.30
- RLI 60.33
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.